Amedisys Home Health and Hospice Care (AMED) Given Consensus Rating of “Buy” by Brokerages

Amedisys Home Health and Hospice Care (NASDAQ:AMED) has earned a consensus rating of “Buy” from the fourteen research firms that are currently covering the stock, MarketBeat.com reports. Five research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $63.88.

Several equities analysts have weighed in on the company. BidaskClub raised Amedisys Home Health and Hospice Care from a “strong sell” rating to a “sell” rating in a report on Wednesday, February 7th. Zacks Investment Research raised Amedisys Home Health and Hospice Care from a “hold” rating to a “buy” rating and set a $57.00 price objective for the company in a report on Tuesday, February 6th. TheStreet cut Amedisys Home Health and Hospice Care from a “b” rating to a “c+” rating in a report on Wednesday, February 28th. Oppenheimer lifted their price objective on Amedisys Home Health and Hospice Care from $68.00 to $63.00 and gave the company an “outperform” rating in a report on Thursday, March 1st. Finally, Robert W. Baird set a $66.00 price objective on Amedisys Home Health and Hospice Care and gave the company a “hold” rating in a report on Thursday, March 1st.

NASDAQ:AMED traded down $1.01 during mid-day trading on Thursday, hitting $64.27. 428,169 shares of the stock were exchanged, compared to its average volume of 294,088. The stock has a market cap of $2,257.95, a P/E ratio of 29.08, a PEG ratio of 1.27 and a beta of 0.65. The company has a current ratio of 1.45, a quick ratio of 1.45 and a debt-to-equity ratio of 0.15. Amedisys Home Health and Hospice Care has a fifty-two week low of $45.60 and a fifty-two week high of $68.50.

Amedisys Home Health and Hospice Care (NASDAQ:AMED) last released its quarterly earnings results on Tuesday, February 27th. The health services provider reported $0.56 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.58 by ($0.02). The firm had revenue of $404.24 million for the quarter, compared to analyst estimates of $394.96 million. Amedisys Home Health and Hospice Care had a return on equity of 15.14% and a net margin of 1.98%. During the same period in the previous year, the business posted $0.44 earnings per share. sell-side analysts forecast that Amedisys Home Health and Hospice Care will post 3 EPS for the current year.

Several institutional investors and hedge funds have recently modified their holdings of the company. American Century Companies Inc. increased its stake in shares of Amedisys Home Health and Hospice Care by 6.9% in the 4th quarter. American Century Companies Inc. now owns 1,787,136 shares of the health services provider’s stock valued at $94,200,000 after purchasing an additional 115,456 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Amedisys Home Health and Hospice Care by 5.3% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,184,424 shares of the health services provider’s stock valued at $66,280,000 after purchasing an additional 59,481 shares during the last quarter. Millennium Management LLC increased its stake in shares of Amedisys Home Health and Hospice Care by 58.2% in the 4th quarter. Millennium Management LLC now owns 1,048,423 shares of the health services provider’s stock valued at $55,262,000 after purchasing an additional 385,734 shares during the last quarter. Copper Rock Capital Partners LLC grew its position in Amedisys Home Health and Hospice Care by 3.6% during the 4th quarter. Copper Rock Capital Partners LLC now owns 596,014 shares of the health services provider’s stock worth $31,386,000 after acquiring an additional 20,699 shares during the last quarter. Finally, Eaton Vance Management grew its position in Amedisys Home Health and Hospice Care by 67.2% during the 4th quarter. Eaton Vance Management now owns 338,488 shares of the health services provider’s stock worth $17,842,000 after acquiring an additional 136,001 shares during the last quarter. Institutional investors own 95.41% of the company’s stock.

Amedisys Home Health and Hospice Care Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

Analyst Recommendations for Amedisys Home Health and Hospice Care (NASDAQ:AMED)

Receive News & Ratings for Amedisys Home Health and Hospice Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Home Health and Hospice Care and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks: Middlefield Banc  Given Consensus Recommendation of “Strong Buy” by Brokerages
Zacks: Middlefield Banc Given Consensus Recommendation of “Strong Buy” by Brokerages
Starwood Property Trust  Given Consensus Recommendation of “Buy” by Brokerages
Starwood Property Trust Given Consensus Recommendation of “Buy” by Brokerages
Dai  Achieves Market Capitalization of $36.36 Million
Dai Achieves Market Capitalization of $36.36 Million
Tattoocoin   Achieves Market Cap of $476,659.00
Tattoocoin Achieves Market Cap of $476,659.00
EMCORE Co.  Given Average Rating of “Hold” by Brokerages
EMCORE Co. Given Average Rating of “Hold” by Brokerages
P.F. Chang's China Bistro  Bonds Trading 1.5% Lower
P.F. Chang's China Bistro Bonds Trading 1.5% Lower


© 2006-2018 Ticker Report. Google+.